Neoadjuvant chemotherapy for advanced eyelid and periocular sebaceous gland carcinoma: a study of 25 cases
International Ophthalmology · 2024
DOI: 10.1007/s10792-024-03256-w ↗Kurz gefasst
Fachartikel in der Zeitschrift International Ophthalmology, 2024. Verfasst von Vijitha S Vempuluru und 5 weiteren Autor:innen. Beteiligte Einrichtung: The Operation Eyesight Universal Institute for Eye Cancer, LV Prasad Eye Institute, L V Prasad Marg, Road No 2, Banjara Hills, Hyderabad, Telangana, …. Hauptthemen laut MEDLINE: Eyelid Neoplasms, Sebaceous Gland Neoplasms, Neoadjuvant Therapy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Hyderabad Eye Research Foundation.
Themen: Onkologische Pflege
Abstract (Originalsprache)
PURPOSE: To report the outcomes of platinum-based neoadjuvant chemotherapy (NACT) for eyelid and periocular sebaceous gland carcinoma (eSGC). METHODS: Retrospective study of 25 patients. RESULTS: The mean age at presentation of eSGC was 59 years. The mean tumor basal diameter was 46 mm. By the 8th edition of AJCC classification, tumors belonged T2 (n = 2, 8%), T3 (n = 6, 24%), and T4 (n = 17, 68%); N1 (n = 12,48%); and M1 (n = 1, 4%). NACT with 5-fluorouracil (5-FU) and cisplatin/carboplatin was administered in 21 (84%)/4 (16%) patients, respectively. The mean number of cycles of neoadjuvant systemic chemotherapy per patient was 2 (median, 3). The mean percentage reduction of tumor basal volume after neoadjuvant chemotherapy was 65% (median, 60%). After NACT, 12 (48%) patients underwent surgical treatment, 6 (12%) patients underwent EBRT, and 4 (8%) underwent adjuvant chemotherapy. A total of 11 (44%) patients were lost to follow-up during the course of treatment, of whom 3 died from metastatic disease. In 16 patients followed up for ≥ 3 months, complete tumor control was achieved in 11 (69%) patients, local tumor control in 14 (88%), and globe salvage in 7 (44%) at a mean follow-up of 25 months (median, 7 months; range, 3 to 110 months). No tumor recurrence was seen in any case. One (4%) serious adverse event of cardiotoxicity was noted. CONCLUSION: Platinum-based NACT is a suitable option for eSGC with advanced tumors and locoregional metastasis. Adverse events are rare and in patients compliant with treatment, NACT-based combination therapy offers globe salvage and systemic tumor control.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Operation Eyesight Universal Institute for Eye Cancer, LV Prasad Eye Institute, L V Prasad Marg, Road No 2, Banjara Hills, Hyderabad, Telangana, 500034, India.
- The Operation Eyesight Universal Institute for Eye Cancer, LV Prasad Eye Institute, L V Prasad Marg, Road No 2, Banjara Hills, Hyderabad, Telangana, 500034, India. kalikiswathi@yahoo.com.
Förderung
- Hyderabad Eye Research Foundation
Zitieren
APA
Vempuluru, V. S., Sinha, P., Tanna, V., Maniktala, Y., Palkonda, V. A. R., & Kaliki, S. (2024). Neoadjuvant chemotherapy for advanced eyelid and periocular sebaceous gland carcinoma: a study of 25 cases. International Ophthalmology. https://doi.org/10.1007/s10792-024-03256-w
Vancouver
Vempuluru VS, Sinha P, Tanna V, Maniktala Y, Palkonda VAR, Kaliki S. Neoadjuvant chemotherapy for advanced eyelid and periocular sebaceous gland carcinoma: a study of 25 cases. International Ophthalmology. 2024. doi:10.1007/s10792-024-03256-w
BibTeX
@article{Vempuluru2024,
author = {Vempuluru, Vijitha S and Sinha, Prerna and Tanna, Vishakha and Maniktala, Yamini and Palkonda, Vijay Anand Reddy and Kaliki, Swathi},
title = {Neoadjuvant chemotherapy for advanced eyelid and periocular sebaceous gland carcinoma: a study of 25 cases},
journal = {International Ophthalmology},
year = {2024},
doi = {10.1007/s10792-024-03256-w}
}
EUVIMED